{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:18:16Z","timestamp":1788499096983,"version":"build-2803163510"},"reference-count":42,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["24-45-00032"],"award-info":[{"award-number":["24-45-00032"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"award":["24-45-00032"],"award-info":[{"award-number":["24-45-00032"]}],"id":[{"id":"https:\/\/ror.org\/03y2gwe85","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as an important class of medications for managing type 2 diabetes and obesity, with cardiovascular outcome trials demonstrating reductions in major adverse cardiovascular events (MACEs) for several agents. The SELECT trial, which enrolled 17,604 participants with established cardiovascular disease and overweight or obesity but without diabetes, showed a 20% reduction in MACEs with semaglutide compared with placebo. Importantly, mediation analyses indicated that weight loss accounted for approximately one-third of this cardiovascular benefit, suggesting that additional mechanisms contribute substantially to the observed risk reduction. The temporal dissociation between weight loss and early MACEs reduction supports the hypothesis that GLP-1RAs exert direct vascular protective effects independent of their metabolic actions. This review synthesizes current evidence on the thromboinflammatory mechanisms through which GLP-1RAs may exert their cardiovascular benefits, with particular emphasis on the neutrophil\u2013NET axis, platelet function, and plaque stabilization. Overall, thromboinflammation represents a biologically reasonable candidate mechanism, but its contribution to the cardiovascular benefit of GLP-1RAs treatment is an open question. Still, residual treatment effects cannot be attributed specifically to thromboinflammation, because metabolic, renal, hemodynamic, and vascular pathways, among others, may also contribute.<\/jats:p>","DOI":"10.3390\/cells15171578","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:08:58Z","timestamp":1788142138000},"page":"1578","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Weight Loss: Thromboinflammation as a Candidate Mechanism for the Cardiovascular Benefit of GLP-1 Receptor Agonists"],"prefix":"10.3390","volume":"15","author":[{"given":"Ivan","family":"Melnikov","sequence":"first","affiliation":[{"name":"Smirnov Institute of Experimental Cardiology, Chazov National Medical Research Center of Cardiology, 121552 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3596-5470","authenticated-orcid":false,"given":"Daria","family":"Borodko","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Genetic Modeling of Inflamaging, Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6497-9794","authenticated-orcid":false,"given":"Vyacheslav","family":"Alekseev","sequence":"additional","affiliation":[{"name":"Laboratory of Neurobiology and Fundamentals of Brain Development, National Medical Research Center of Children\u2019s Health, 119991 Moscow, Russia"},{"name":"Department of Cell Biology and Histology, Biological Faculty, Lomonosov Moscow State University, 119234 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8388511","DOI":"10.1155\/cdr\/8388511","article-title":"Direct or Indirect Action? Mechanisms of the Antiatherosclerotic Effects of Glucagon-Like Peptide-1 Receptor Agonists","volume":"2026","author":"Zawadzki","year":"2026","journal-title":"Cardiovasc. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: A prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e00346","DOI":"10.1097\/XCE.0000000000000346","article-title":"Improved cardiovascular outcomes with glucagon-like peptide-1 receptor agonists\u2014What is the role of weight reduction?","volume":"14","author":"Jacob","year":"2025","journal-title":"Cardiovasc. Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical prctice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s12933-025-03007-w","article-title":"Temporal and subgroup disparities in mediation effects on cardiovascular outcomes with liraglutide and semaglutide: A post-hoc analysis of LEADER and SUSTAIN-6 trials","volume":"24","author":"Peng","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","article-title":"The cardiovascular biology of glucagon-like peptide-1","volume":"24","author":"Drucker","year":"2016","journal-title":"Cell Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1210\/er.2011-1052","article-title":"Cardiovascular biology of the incretin system","volume":"33","author":"Ussher","year":"2012","journal-title":"Endocr. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1210\/clinem\/dgag218","article-title":"Anti-inflammatory effects of GLP1-RA drugs","volume":"111","author":"Quintana","year":"2026","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE\u2212\/\u2212 and LDLr\u2212\/\u2212 Mice by a Mechanism That Includes Inflammatory Pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/jpet.119.258343","article-title":"Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators","volume":"370","author":"Bruen","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e20710","DOI":"10.7717\/peerj.20710","article-title":"The effects of GLP-1 receptor agonists on metabolic inflammatory markers in patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"14","author":"Zhao","year":"2026","journal-title":"PeerJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice","volume":"54","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"key":"ref_20","first-page":"1","article-title":"Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network","volume":"23","author":"Bravo","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jacbts.2022.04.004","article-title":"Glucagon-like peptide-1 receptor regulates thromboxane-induced human platelet activation","volume":"7","author":"Cahill","year":"2022","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"39927","DOI":"10.31083\/RCM39927","article-title":"An Association Between GLP-1 Receptor Expression on Regulatory T Cells and the Severity of Coronary Artery Stenosis and Inflammatory Dysregulation in Coronary Heart Disease","volume":"26","author":"Lv","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/en.2003-1336","article-title":"Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans","volume":"145","author":"Fain","year":"2004","journal-title":"Endocrinology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.coph.2005.01.007","article-title":"Plasminogen activator inhibitor-1: A common denominator in obesity, diabetes and cardiovascular disease","volume":"5","author":"Smith","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s00109-005-0688-7","article-title":"Understanding RAGE, the receptor for advanced glycation end products","volume":"83","author":"Bierhaus","year":"2005","journal-title":"J. Mol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1089\/ars.2015.6317","article-title":"Clinical relevance of biomarkers of oxidative stress","volume":"23","author":"Frijhoff","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00592-014-0676-x","article-title":"NETosis is induced by high glucose and associated with type 2 diabetes","volume":"52","author":"Menegazzo","year":"2015","journal-title":"Acta Diabetol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.aaa8064","article-title":"Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis","volume":"349","author":"Warnatsch","year":"2015","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"aaf1098","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: A program of innate immune memory in health and disease","volume":"352","author":"Netea","year":"2016","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1161\/CIRCRESAHA.117.312494","article-title":"Roles of PAD4 and NETosis in Experimental Atherosclerosis and Arterial Injury: Implications for Superficial Erosion","volume":"123","author":"Franck","year":"2018","journal-title":"Circ. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/CIRCRESAHA.116.309692","article-title":"Neutrophil extracellular traps in atherosclerosis and atherothrombosis","volume":"120","author":"Soehnlein","year":"2017","journal-title":"Circ. Res."},{"key":"ref_32","unstructured":"ClinicalTrials.gov (2025). Impact of Antiglycemic & Immunosuppressive Therapies on NETosis in Diabetes & Kidney Disease, Identifier: NCT06821919."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2174\/1871530319666191014110414","article-title":"A review on the effects of new anti-diabetic drugs on platelet function","volume":"20","author":"Yaribeygi","year":"2020","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"108188","DOI":"10.1016\/j.jdiacomp.2022.108188","article-title":"A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study)","volume":"36","author":"Loganathan","year":"2022","journal-title":"J. Diabetes Complicat."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e194748","DOI":"10.1172\/JCI194748","article-title":"GLP-1 and the cardiovascular system","volume":"136","author":"Kahles","year":"2026","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2010.12.131","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury","volume":"405","author":"Goto","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Jensen, J.K., Zobel, E.H., von Scholten, B.J., Rotbain Curovic, V., Hansen, T.W., Rossing, P., Kjaer, A., and Ripa, R.S. (2021). Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET\/CT: Results from the LIRAFLAME Trial. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.790405"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00592-025-02606-z","article-title":"GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes","volume":"63","author":"Gitto","year":"2026","journal-title":"Acta Diabetol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12933-022-01585-7","article-title":"Impact of semaglutide on high-sensitivity C-reactive protein: Exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials","volume":"21","author":"Mosenzon","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bbrc.2018.03.142","article-title":"Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1\/NOX4\/ROS pathway in H9c2 cells","volume":"499","author":"Chen","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/17\/1578\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:43:56Z","timestamp":1788497036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/17\/1578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":42,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cells15171578"],"URL":"https:\/\/doi.org\/10.3390\/cells15171578","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]}}}